Last reviewed · How we verify
CEFTAROLINE FOSAMIL ACETATE
At a glance
| Generic name | CEFTAROLINE FOSAMIL ACETATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2010 |
Approved indications
Common side effects
Key clinical trials
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (PHASE3)
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (PHASE3)
- Ceftaroline in the Treatment of Bone and Joint Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFTAROLINE FOSAMIL ACETATE CI brief — competitive landscape report
- CEFTAROLINE FOSAMIL ACETATE updates RSS · CI watch RSS